Statement Of Cash Flows [Abstract]

Medistim - Filing #2546555

Concept As at
2023-12-31
2023-01-01 to
2023-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
103 823 NOK
113 973 NOK
Adjustments to reconcile profit (loss) [abstract]
Adjustments for decrease (increase) in inventories
31 058 NOK
16 920 NOK
Adjustments for decrease (increase) in trade accounts receivable
27 354 NOK
33 023 NOK
Adjustments for increase (decrease) in trade accounts payable
613,000 NOK
11 265 NOK
Cash flows from (used in) operating activities
113 189 NOK
113 491 NOK
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
16 399 NOK
9 251 NOK
Cash flows from (used in) investing activities
29 726 NOK
21 102 NOK
Cash flows from (used in) financing activities [abstract]
Payments of lease liabilities, classified as financing activities
8 712 NOK
7 312 NOK
Dividends paid, classified as financing activities
82 180 NOK
68 396 NOK
Other inflows (outflows) of cash, classified as financing activities
6 009 NOK
5 404 NOK
Cash flows from (used in) financing activities
84 883 NOK
70 304 NOK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
2 651 NOK
1 066 NOK
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes
1 231 NOK
23 151 NOK
Cash and cash equivalents
146 082 NOK
144 164 NOK

Talk to a Data Expert

Have a question? We'll get back to you promptly.